Hence, transcriptional deregulation may sensitize cancer cells to PARP inhibitors, as shown for DNA-repair proficient HER2-positive breast cancer cells whereby NF-κB overactivation is attenuated through PARP inhibition (Nowsheen et al. 2012). This evidence concerns the gene PARP1 and breast carcinoma.